Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat DME. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740
Debt
Debt-to-Equity Ratio-0.62
Current Ratio4.81
Quick Ratio4.64
Price-To-Earnings
Trailing P/E Ratio-3.03
Forward P/E Ratio-2.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.91 million
Price / Sales1.72
Cash FlowN/A
Price / CashN/A
Book Value($0.78) per share
Price / Book-1.13
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-22,000,000.00
Net Margins-58.70%
Return on EquityN/A
Return on Assets-29.73%
Miscellaneous
Employees126
Outstanding Shares70,040,000
Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.07. The biopharmaceutical company had revenue of $9.14 million for the quarter, compared to analyst estimates of $9.60 million. View Alimera Sciences' Earnings History.
When is Alimera Sciences' next earnings date?
What price target have analysts set for ALIM?
2 brokers have issued 1-year price targets for Alimera Sciences' stock. Their predictions range from $3.00 to $3.00. On average, they expect Alimera Sciences' stock price to reach $3.00 in the next twelve months. View Analyst Ratings for Alimera Sciences.
What are Wall Street analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. HC Wainwright analysts commented, "We note that less than a third of chronic DME patients in England and Wales have an artificial lens. Therefore, if reimbursement of Iluvien is available to all DME patients in UK, Alimera’s revenue from UK could increase significantly. Management expects the Technology Assessment 301 part-appraisal to be completed in 2019. In the wake of this update, we reiterate our Buy rating and $2.50 price target." (6/12/2018)
- 2. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (5/11/2018)
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Sierra Oncology (SRRA), Aeglea Bio Therapeutics (AGLE), Avadel Pharmaceuticals (AVDL), ProQR Therapeutics (PRQR), Chimerix (CMRX), Melinta Therapeutics (MLNT), Galmed Pharmaceuticals (GLMD), Aratana Therapeutics (PETX), Poxel (PXXLF), Immune Design (IMDZ), Kamada (KMDA), Spero Therapeutics (SPRO), Ovid Therapeutics (OVID), Teligent (TLGT) and Tetraphase Pharmaceuticals (TTPH).
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Mr. Charles Daniel Myers, Co-Founder, CEO & Director (Age 64)
- Mr. Richard S. Eiswirth Jr., Pres & CFO (Age 50)
- Dr. Kenneth Green, Sr. VP & Chief Scientific Officer (Age 60)
- Mr. David R. Holland, Co-Founder and Sr. VP of Sales & Marketing (Age 54)
- Mr. Jeffrey W. Burris, VP, Gen. Counsel & Sec. (Age 46)
Has Alimera Sciences been receiving favorable news coverage?
Media stories about ALIM stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alimera Sciences earned a news sentiment score of 0.15 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Alimera Sciences' major shareholders?
Alimera Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include JW Asset Management LLC (0.99%). Company insiders that own Alimera Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.
Which institutional investors are selling Alimera Sciences stock?
ALIM stock was sold by a variety of institutional investors in the last quarter, including JW Asset Management LLC. Company insiders that have sold Alimera Sciences company stock in the last year include C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.
How do I buy shares of Alimera Sciences?
Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of ALIM stock can currently be purchased for approximately $0.8799.
How big of a company is Alimera Sciences?
Alimera Sciences has a market capitalization of $61.63 million and generates $35.91 million in revenue each year. The biopharmaceutical company earns $-22,000,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Alimera Sciences employs 126 workers across the globe.
How can I contact Alimera Sciences?
Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]
MarketBeat Community Rating for Alimera Sciences (ALIM)
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
